US FDA Inspection Concludes at Aurobindo Pharma Subsidiary, Four Procedural Observations Noted
The United States Food and Drug Administration (US FDA) conducted a routine inspection at Lannett Company LLC, a wholly owned step-down subsidiary of Aurobindo Pharma, located in Seymour, IN, USA. The inspection, which took place from August 17 to August 21, 2026, concluded with the identification of four procedural observations.Aurobindo Pharma Limited confirmed that the inspection at the facility is complete. The observations noted by the US FDA are procedural in nature, and the company is committed to responding to the regulatory body within the stipulated timeline.
Lannett Company LLC is a wholly owned subsidiary of Aurobindo Pharma. The company reaffirmed its commitment to maintaining robust quality and compliance standards across its manufacturing facilities in the United States.
Aurobindo Pharma will provide updates regarding any further developments related to the inspection and the subsequent actions taken.
AUROPHARMA Stock Price Movement
As of 9:19 AM, shares of Aurobindo Pharma Limited are slipping by 0.47%, currently trading at ₹1613.6. The stock has seen a relatively subdued session so far today, with 2,651 shares traded in the live market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.